Search
Altimmune Inc
ALTAdd to Watchlist
3.160USD
+0.010+0.32%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
350.39MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.32%
5 Days
+12.06%
1 Month
+8.22%
6 Months
-9.97%
Year to Date
-12.47%
1 Year
-33.61%
Key Figures
3.180Open
3.260High
4.08MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.68%Turnover Ratio
3.150Prev. Close
3.100Low
9.62MTurnover
LossP/E Static
1.56P/B
0.00%Div Yield TTM
-36.96%ROA
7.73052wk High
0.93Volume Ratio
-95.06MNet Profit
110.88MShares
-0.9220EPS TTM
0.20Beta
-42.75%ROE
2.56052wk Low
5.06%Amplitude
100.00%Gross Margin
350.39MMarket Cap
2.12Reward/Risk
3.72%Risk Rate
TradingKey Stock Score of Altimmune Inc
Currency: USD Updated: 2026-07-02Key Insights
Altimmune Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 102 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.23.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Altimmune Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Altimmune Inc Highlights
StrengthsRisks
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Growing
The company is in a growing phase, with the latest annual income totaling USD 41.00K.
Fairly Valued
The company’s latest PE is -3.43, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 57.72M shares, increasing 7.43% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 687.92K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
16.227
Target Price
+415.15%
Upside Space
Altimmune Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Altimmune Inc Info
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Ticker SymbolALT
CompanyAltimmune Inc
CEODurso (Jerome Benedict)
Websitehttps://altimmune.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Altimmune Inc (ALT)?
The current price of Altimmune Inc (ALT) is 3.16.
What is the symbol of Altimmune Inc?
The ticker symbol of Altimmune Inc is ALT.
What is the 52-week high of Altimmune Inc?
The 52-week high of Altimmune Inc is 7.73.
What is the 52-week low of Altimmune Inc?
The 52-week low of Altimmune Inc is 2.56.
What is the market capitalization of Altimmune Inc?
The market capitalization of Altimmune Inc is 350.39M.
Is Altimmune Inc (ALT) currently rated as Buy, Hold, or Sell?
According to analysts, Altimmune Inc (ALT) has an overall rating of Buy, with a price target of 16.23.
What is the Earnings Per Share (EPS TTM) of Altimmune Inc (ALT)?
The Earnings Per Share (EPS TTM) of Altimmune Inc (ALT) is -1.00.